FIELD: medicine.
SUBSTANCE: presented invention refers to immunology. Disclosed are versions of a human antibody or an antigen-binding fragment of the human antibody, which specifically bind and inhibit human proprotein convertase subtilisin/kexin type 9 (hPCSK9). Each version is characterised by the fact that it contains 6 CDRs of heavy and light chains. Described are: an isolated coding nucleic acid, and expression vector and a method for producing the antibody with the use of the above vector. Presented is a pharmaceutical formulation based on the antibody for treating a disease or a condition which can be relieved, improved, suppressed or prevented by means of the anti-PCSK9 antibody.
EFFECT: using the invention provides the new versions of the antibodies able to reduce serum low-density lipoprotein cholesterol accompanied by no considerable changes or no effect on the hepatic function according to measured alanine-aminotransferase and aspartate-aminotransferase.
8 cl, 14 dwg, 28 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
HIGH AFFINITY HUMAN PCSK9 ANTIBODIES | 2009 |
|
RU2697773C2 |
HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS | 2012 |
|
RU2603481C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES TO HUMAN PCSK9 | 2012 |
|
RU2604139C2 |
ANTI-ANGPTL3 ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2620064C2 |
PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS | 2012 |
|
RU2721279C2 |
PCSK9 ANTAGONISTS | 2014 |
|
RU2618869C2 |
ANTIBODIES WITH PH-DEPENDENT ANTIGEN BINDING | 2011 |
|
RU2570729C2 |
ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
HUMANISED ANTI-TAU ANTIBODIES | 2015 |
|
RU2743152C2 |
Authors
Dates
2015-06-10—Published
2009-12-15—Filed